High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Health coverage company Centene (NYSE:CNC) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.9% year on year to $53.58 billion. The company’s full-year revenue guidance of $195.5 billion at the midpoint came in 2.7% above analysts’ estimates. Its non-GAAP profit of $2.51 per share was significantly above analysts’ consensus estimates.
Today Earnings (a.m.): Coca-Cola, UPS, Boeing, Sherwin-Williams, Hilton, Centene, PayPal, S&P Global Earnings (p.m.): Visa, Ford Motor, Mondelez International, Waste Management, PPG Industries, Bloom Energy, Avis Budget, Seagate Technology Economic data: Consumer confidence index, Johnson Redbook retail sales index, U.
Health coverage company Centene (NYSE:CNC) will be reporting results this Tuesday before market open. Here’s what you need to know.
The healthcare giant looks expensive on today's numbers, but a patient investor is effectively buying it at a significant discount to that price.
Beyond analysts' top-and-bottom-line estimates for Centene (CNC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
CNC reports Q2 results July 28 as investors weigh improving profitability against membership declines and revenue pressure ahead of earnings.
UnitedHealth's stock is flying high after it raised guidance, but on its latest earnings call, analysts zeroed in on an underlying margin divergence running right through the business.
The stock is trading near 52-week highs, but under the surface, commercial segment cost trends are creating headwinds.
The health insurer raised its forecast after a solid quarter, but investors focused on the one business so broken it’s forcing a strategic retreat.
Centene’s updated price target framework now reflects a fair value revision from US$61.83 to US$63.78, a modest uplift that has caught investor attention. Research commentary links this shift to a more constructive view on Centene’s earnings power, supported by trends in exchanges, Medicare Advantage, and early signs of Medicaid margin recovery, while still pointing out execution and policy risks. As you read on, you will see how this evolving analyst narrative may matter for your own view of...
Elevance Health raised its profit forecast and the stock promptly fell. Here’s the one number that explains why investors headed for the exits.
The core narrative surrounding UnitedHealth Group (UNH) is dominated by its successful margin recovery, yet the underlying data reveal a shift from a growth compounder to a vulnerable margin defender. The defining insight is not the massive bottom-line beat of a $6.38 adjusted earnings per share against a $4.94 consensus estimate. Rather, it is the deliberate contraction of the core membership base to support margins in the face of significant regulatory headwinds.
The stock is priced for strength, but a deep and persistent drag from one of its largest divisions could challenge the optimistic narrative.
UnitedHealth Group crushed Q2 earnings forecasts amid lower-than-expected benefit costs and gave a big boost to its full-year outlook. Humana, Centene and CVS Health all got a sizable lift from the warm reception for UnitedHealth's earnings report.
Skittish investors pushed Elevance shares down, as they focused on worries about its Medicaid business. CEO Gail Boudreaux said the insurer’s Medicaid results were roughly what it expected, but the company is leaving the District of Columbia’s Medicaid market and plans to exit others over the next year to 18 months.
Elevance Health topped Q2 earnings estimates Wednesday, despite falling medical membership, but profit was boosted by one-time "below-the-line" factors and the full-year outlook was underwhelming. ELV stock tumbled, making it among the S&P 500's early laggards. Molina Healthcare, another S&P 500 managed care stock, joined Elevance among the biggest laggards performers in pre-market trading.
Investing.com -- Elevance Health’s Health Benefits operating profit collapsed in the second quarter of 2026, igniting a broad premarket selloff across the managed-care sector even as the insurer’s headline earnings handily beat estimates and full-year guidance was lifted.
Elevance Health is breaking the Medicare Advantage curse, and the insurer’s earnings could show it on Wednesday. Health insurer stocks have rallied this year after a tough run of rising medical costs that hampered earnings in 2024 and 2025. The results come just a day ahead of the monster of the industry, UnitedHealth Group Wall Street will be watching to see if these two companies can keep the momentum going.
CNC stock's 66% rally reflects improving margins, stronger cash flow and renewed earnings growth, but can the turnaround keep gaining momentum?
Harris Oakmark recently released its second-quarter 2026 investor letter for the “Oakmark Select Fund”. A copy of the letter can be downloaded here. Oakmark Select Fund is a non-diversified fund that aims to deliver capital appreciation by investing in mid- and large-cap US companies. In the quarter, the Fund (investor class) trailed the S&P 500 […]
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
After a rocky start to the year, health insurer stocks have roared back. The insurers are trying to end a difficult cycle that began about three years ago, when healthcare use, and the costs to cover it, accelerated postpandemic. The fund’s top 10 holdings encompass six health insurers, three of which— UnitedHealth Group Aetna parent CVS Health and Elevance Health —comprise more than 40% of the fund.
Centene stock has more than doubled over the past year, yet the valuation checks still lean on the cheap side. This raises a clear question about whether the recent share price strength has fully reflected the current fundamentals. Over the past 12 months, Centene has returned 114.2%, which puts recent enthusiasm for the stock squarely in focus for anyone thinking about valuation today. Contract wins in Medicaid managed care can support confidence in the durability of Centene’s cash flows...
Index moves put Centene’s growth profile in focus Centene (CNC) has been dropped from Russell’s defensive and value defensive indexes and added to several growth benchmarks, a reshuffle that changes how many index funds and style focused investors may view the stock. See our latest analysis for Centene. At a share price of $67.35, Centene’s 90 day share price return of 80.56% and 1 year total shareholder return of 114.22% point to strong momentum. However, the 5 year total shareholder return...
Centene secures a four-year Illinois Medicaid contract renewal, preserving a key membership base and reinforcing long-term revenue stability.
Private-equity firm Warburg Pincus is near a deal to buy specialty-pharmacy company PantheRx Rare for over $7 billion, including debt, according to people familiar with the matter. PantheRx Rare is owned by an investor consortium that includes private-equity firm General Atlantic. A deal could come together soon, the people said, cautioning that nothing is finalized and the timing could still slip.
In late June 2026, Centene’s Illinois subsidiary Meridian Health Plan of Illinois secured a four‑year renewal to continue serving the HealthChoice Illinois Medicaid managed care program from 2027 to 2030, while Centene was also reclassified into several Russell growth benchmarks and removed from certain defensive and value‑defensive indexes. This combination of a large Medicaid contract renewal in a key state and index moves toward growth benchmarks highlights Centene’s evolving profile as...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
